What changed, and what the rule does not decide
G.S.R. 743(E), notified on 14 August 2026 and published in Gazette No. 677 dated 19 August 2026, adds a Rule 44 label requirement when sterilization is outsourced to another facility holding a valid licence to carry out medical-device sterilization. The amendment states that compliance with the new clause becomes mandatory six months from the notification. It does not by itself resolve whether a specific arrangement, licence, label, validation package or biological-evaluation file is adequate.
The legal source position has changed since the June 2025 administrative letter. G.S.R. 743(E) adds a final Rule 44 labelling requirement for the covered outsourced-sterilization arrangement and inserts a Ninth Schedule fee framework. Biological-evaluation consequences remain device- and change-specific: the final amendment does not make new testing automatic.
What CDSCO Published
On 24 June 2025, DCGI issued an administrative letter communicating adopted recommendations on outsourced sterilization. Draft G.S.R. 270(E) followed on 10 April 2026. G.S.R. 743(E), notified on 14 August and published in Gazette No. 677 dated 19 August 2026, is the final amendment arising from that proposal. It adds Rule 44 clause (p), inserts the Ninth Schedule, and amends Rules 19 and 69 to connect that schedule to specified test or evaluation fees.
The amendment does not itself approve a specific outsourcing arrangement, determine portal practice, validate a contract, QMS or sterilization cycle, or decide whether existing biological evidence remains representative. Those questions require the current Rules as amended plus the applied licensing, device, process and evidence facts.
Why This Matters to the Biocompatibility File
- Finished-device representation: biological evaluation should reflect the device state that actually reaches the patient, including the sterilized state.
- Residual and process logic: EO or other sterilization-related residues, hold times, and process-dependent assumptions can affect chemistry and risk framing.
- Packaging interaction: when sterilization and sterile barrier logic are linked, packaging cannot be treated as a disconnected afterthought.
- Change control: an outsourced process step creates another place where a vendor, cycle, load, or validation change can quietly make an old rationale incomplete.
- Comparability questions: if the file relies on older testing or chemistry work, teams may need to explain why the current sterilized article is still represented by that evidence.
When an Existing File Deserves a Recheck
- New sterilization vendor: even where the modality is unchanged, process ownership and validation context have shifted.
- Cycle or parameter changes: exposure conditions, aeration logic, or load configuration can change the real finished-device state.
- Packaging updates: sterile barrier and packaging process changes can alter what the file should say about final article representation.
- Material or additive sensitivity: some device materials are more likely to raise chemistry or residual questions after process changes.
- India filing work beginning now: old global documents often underdescribe the current sterilization control story.
What India Teams Should Prepare
- A clean description of the current sterilization arrangement and the role of the external provider
- Change-control logic showing whether the outsourced process affects the final article representation used in the file
- Updated device description language where sterilization state matters to chemistry or biological evaluation conclusions
- Packaging and sterile barrier context where relevant
- A documented rationale for why existing data remains representative, or what needs selective remediation
The final amendment has been published; compliance with Rule 44(p) becomes mandatory six months from the notification. Whether the outsourcing change affects finished-device representation, chemistry, residuals, packaging or existing biocompatibility evidence is a separate scientific and change-control assessment. A documented impact assessment is warranted; new testing is not automatic.
Best Next Step for Manufacturers
Verify the applied licence and labelling position through the responsible India regulatory function, then review the finished-device description, sterilization validation, chemistry assumptions, packaging context and evidence-applicability logic. Do not treat the final amendment as automatic approval of an arrangement or as an automatic instruction to repeat testing.
The available Medical Device Change Control and Evidence Decisions handbook expands this reasoning beyond biological impact to baseline control, cumulative change, evidence applicability, authorization, market-route questions and post-implementation monitoring. It does not make a device-specific India filing or implementation decision.
Official References
Why this perspective is practical
Arvind Rathore is the founder of MedDev Advisory, where his work focuses on ISO 10993 biological-evaluation strategy and documentation. Before establishing the practice, he was a Marie Skłodowska-Curie Early Stage Researcher at INSERM U1026 Biotis within the ImplantSens network. His research covered implantable electrochemical biosensors, cytotoxicity, oxidative stress, sterilization effects and biomaterial–cell interactions, with research placements in France, Germany and Sweden. Peer-reviewed work in Bioelectrochemistry and Advanced Sensor Research also informs his evidence-led approach. Read more about Arvind Rathore.
The problem is often not the notice itself. It is the older file that no longer matches the current device and process story.
A focused review can show whether sterilization outsourcing has only operational consequences, or whether the biological evaluation and change-control logic also need cleanup.